AudioScholar Pulmonary Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

Pulmonary — a weekly podcast briefing of the most significant peer-reviewed pulmonary literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 5d ago

    This Week in Pulmonary — Oct 27, 2026

    Editor's Pick: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (New England Journal of Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning a wave of phase 3 thoracic oncology trials, eosinophilic airway and vasculitic disease, and practical questions in infection and acute pulmonary embolism. This week's papers: 1. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. — New England Journal of Medicine 2026 2. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. — New England Journal of Medicine 2026 3. Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. — New England Journal of Medicine 2026 4. Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generati… — The Lancet 2026 5. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-L… — The Lancet 2026 6. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. — New England Journal of Medicine 2026 7. Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial. — JAMA 2026 8. Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database. — International Journal of Chronic Obstructive Pulmonary Disease 2026 9. Cavitary status and differential treatment response in refractory or severe Mycobacterium avium complex pulmonary disease: Amikacin liposome inhalation suspens… — Respiratory Medicine 2026 10. Low end-tidal carbon dioxide identifies high-severity pulmonary embolism and shock-level haemodynamics. — ERJ Open Research 2026 Listen at https://audioscholar.cc/episode/fqqcpfwyv3

  2. Oct 20

    This Week in Pulmonary — Oct 20, 2026

    Editor's Pick: Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial (JAMA, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning acute respiratory failure and critical care, bronchiectasis and interstitial lung disease, and pneumonia alongside new therapeutics and drug safety. This week's papers: 1. Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial. — JAMA 2026 2. High-Frequency Chest Wall Oscillation in Acute Respiratory Failure With Bronchial Hypersecretion: A Randomized Controlled Trial. — Chest 2026 3. The Prognostic Value of PaCO2 on the Response to Noninvasive Ventilation in Patients with AECOPD Complicated by Type II Respiratory Failure. — International Journal of Chronic Obstructive Pulmonary Disease 2026 4. Association of inhaled corticosteroid use with first Pseudomonas aeruginosa isolation in eosinophilic bronchiectasis: a multicenter retrospective study. — Respiratory Medicine 2026 5. Fertility, pregnancy, and women's health in bronchiectasis: a multicenter study and ELF-EMBARC patient survey. — Chest 2026 6. Safety and diagnostic yield of transbronchial lung cryobiopsy in patients with interstitial lung disease and severe pulmonary function impairment. — Respiratory Research 2026 7. Effect of clarithromycin on the circulating inflammatory proteome in community-acquired pneumonia: a secondary analysis of the ACCESS trial. — Chest 2026 8. Epidemiology, risk factors and clinical outcome of community-acquired pneumonia in severely immunosuppressed patients: a comprehensive analysis from the multin… — ERJ Open Research 2026 9. A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutation. — European Respiratory Journal 2026 10. Multimodal investigation of the association between bevacizumab and pulmonary arterial hypertension. — ERJ Open Research 2026 Listen at https://audioscholar.cc/episode/8kcqdduvun

  3. Oct 13

    This Week in Pulmonary — Oct 13, 2026

    Editor's Pick: 2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes (American Journal of Respiratory and Critical Care Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning asthma strategy and biologic therapy across airway disease, new evidence frameworks for sleep apnoea and metabolic therapies, and acute and critical care questions… This week's papers: 1. 2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes. — American Journal of Respiratory and Critical Care Medicine 2026 2. Scottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and post-remission management in severe asthma. — Respiratory Medicine 2026 3. Real-World Effectiveness of Dupilumab in Patients with Severe Asthma in Europe: Findings from the EU-ADVANTAGE Study. — Respiratory Medicine 2026 4. Real-world effectiveness of dupilumab in COPD: a German multicenter analysis. — Respiratory Research 2026 5. Switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA). — Chest 2026 6. ERS/ESRS clinical practice guideline for continuous positive airway pressure for the treatment of adult obstructive sleep apnoea. — European Respiratory Journal 2026 7. GLP-1-based therapies in lung diseases. — European Respiratory Journal 2026 8. Short and Long-Term Outcomes of Intermediate-High Risk Pulmonary Embolism Treated with Catheter-Directed Reperfusion Therapy Versus Anticoagulation. — Respiratory Medicine 2026 9. Effectiveness of Continuous Automatic Endotracheal Cuff Pressure Monitoring in Preventing Ventilator-Associated Pneumonia in the Pediatric Intensive Care Unit:… — Chest 2026 10. Individualized Treatment Effects of Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection. — American Journal of Respiratory and Critical Care Medicine 2026 Listen at https://audioscholar.cc/episode/zac64e96kg

  4. Oct 6

    This Week in Pulmonary — Oct 6, 2026

    Editor's Pick: Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE) (American Journal of Respiratory and Critical Care Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning chronic airway infection, acute and critical respiratory illness, and the growing population burden of lung disease along with how we screen for and diagnose it. This week's papers: 1. Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCOR… — American Journal of Respiratory and Critical Care Medicine 2026 2. Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis. — ERJ Open Research 2026 3. Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized Clinical Trial (SAFER). — American Journal of Respiratory and Critical Care Medicine 2026 4. TISA-818, an Anti-inflammatory Conjugate of Montelukast-Decapeptide, in Acute Respiratory Distress Syndrome Due to Pulmonary Infection: A Phase 2 Randomized Tr… — Chest 2026 5. Duration of antibiotic therapy in sepsis and severe infections in critically ill patients. — American Journal of Respiratory and Critical Care Medicine 2026 6. Comparative Short-Term Prognostic Discrimination of the 2026 AHA/ACC and 2019 ESC Risk Classifications in Hospitalized Acute Pulmonary Embolism: A Retrospectiv… — Chest 2026 7. The burden and long-term outcomes of diagnosed and underdiagnosed COPD across diverse communities from high-income, middle-income, and low-income countries: th… — The Lancet Global Health 2026 8. End of rarity: the evolving burden of interstitial lung diseases in England - trends from a national population-based cohort study. — Thorax 2026 9. Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial. — JAMA 2026 10. CEUS- versus US- and CT-guided Biopsy for Subpleural Lung Lesions: A Prospective, Multicenter Randomized Controlled Trial. — Chest 2026 Listen at https://audioscholar.cc/episode/y2fxhbz4cp

  5. Sep 29

    This Week in Pulmonary — Sep 29, 2026

    Editor's Pick: Safety of Age-Adjusted and Clinical Probability-Adjusted D-dimer Cut-offs in Suspected Pulmonary Embolism: A Systematic Review and Meta-Analysis (Chest, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning imaging biomarkers in obstructive and vascular lung disease, targeted therapeutics in cystic fibrosis and severe asthma, and risk stratification in the critically… This week's papers: 1. Safety of Age-Adjusted and Clinical Probability-Adjusted D-dimer Cut-offs in Suspected Pulmonary Embolism: A Systematic Review and Meta-Analysis. — Chest 2026 2. Association between Airway Mucus Plugs on Computed Tomography and Respiratory Outcomes in Participants with COPD and with Preserved Spirometry: Findings from a… — American Journal of Respiratory and Critical Care Medicine 2026 3. One-year progression of CT emphysema subtypes predict lung function decline: SPIROMICS. — American Journal of Respiratory and Critical Care Medicine 2026 4. Elexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis. — European Respiratory Journal 2026 5. Tezepelumab effectiveness in Aspirin-Exacerbated Respiratory Disease: a real-world multicenter study. — Respiratory Medicine 2026 6. Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category. — Journal of Thoracic Oncology 2026 7. Biological phenotypes of alveolar injury and immune failure predict mortality in non-HIV Pneumocystis jirovecii pneumonia: a Spanish multicentre cohort study. — Chest 2026 8. Pulmonary Artery Dilation on Chest CT Across the Spectrum of Chronic Lung Disease. — Chest 2026 9. Prognostic impact of coexisting lung disease in patients with pulmonary arterial hypertension. — Respiratory Medicine 2026 10. Cough function during mechanical ventilation. — Chest 2026 Listen at https://audioscholar.cc/episode/t497x5rf96

  6. Sep 22

    This Week in Pulmonary — Sep 22, 2026

    Editor's Pick: Changes in Inhaled Antibiotic Associated lung function outcomes in the CFTR-Modulator Era (Chest, 2026) Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning chronic airway infection and bronchiectasis care, COPD phenotyping and rehabilitation, and a set of papers on diagnostics, epidemiology and sleep-disordered breath… This week's papers: 1. Changes in Inhaled Antibiotic Associated lung function outcomes in the CFTR-Modulator Era. — Chest 2026 2. International epidemiology of antimicrobial resistance in people living with chronic lung infection. — Thorax 2026 3. Non-Cystic Fibrosis Bronchiectasis in the United States: Prevalence Trends in a Large Electronic Health Record Population, 2015-2025. — Chest 2026 4. Delivering Bronchiectasis and NTM Care in Safety-Net Health Systems: A Practical Framework for Implementation. — Chest 2026 5. Mixed Mucus Plug-Emphysema Subtype and Acute Exacerbation in Chronic Obstructive Pulmonary Disease. — Chest 2026 6. Targeting fatigue in COPD with chronic respiratory failure undergoing pulmonary rehabilitation: a multicentre, randomised, placebo-controlled trial of L-argini… — Thorax 2026 7. Multicomponent Pulmonary Rehabilitation for Prolonged Mechanical Ventilation in Patients Aged 80 Years or Older: A Randomized Controlled Trial. — Chest 2026 8. Thoracentesis with pleural fluid cytology versus thoracoscopy with pleural biopsy for the diagnosis of malignant pleural effusion: a cost-effectiveness study. — Chest 2026 9. Generational changes in lung function in adults from several world regions: results from the Burden of Obstructive Lung Disease study. — Thorax 2026 10. Central sleep apnea after stroke: prevalence, mechanisms, and clinical implications. — Chest 2026 Listen at https://audioscholar.cc/episode/fufu7jrhyb

  7. Sep 15

    This Week in Pulmonary — Sep 15, 2026

    Editor's Pick: Assessing the impact of earlier initiation of biologics on clinical remission and other outcomes in a global real-life severe asthma cohort from CHRONICLE, ISAR and OPCRD (Chest, 2026) Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning thoracic oncology, airways disease and respiratory infection risk, interstitial lung disease from genetics to rehabilitation, and the pulmonary vasculature. This week's papers: 1. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy. — New England Journal of Medicine 2026 2. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Tri… — Journal of Thoracic Oncology 2026 3. Assessing the impact of earlier initiation of biologics on clinical remission and other outcomes in a global real-life severe asthma cohort from CHRONICLE, ISA… — Chest 2026 4. Pseudomonas Aeruginosa Abundotypes and Interactotypes Reflect Clinical Heterogeneity in Bronchiectasis. — American Journal of Respiratory and Critical Care Medicine 2026 5. Tuberculosis during JAK inhibitor or TNF-α inhibitors therapy: a disproportionality analysis from WHO pharmacovigilance database. — Thorax 2026 6. Familial pulmonary fibrosis: a UK consensus framework for the investigation and management of patients and their relatives. — Thorax 2026 7. Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis. — Thorax 2026 8. High intensity interval training in interstitial lung disease: a randomized controlled trial. — American Journal of Respiratory and Critical Care Medicine 2026 9. Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH. — Thorax 2026 10. Activin Pathway Inhibition and Rapid Progression of Malignancy in Pulmonary Arterial Hypertension: A Case Series and Hypothesis. — Respiratory Medicine 2026 Listen at https://audioscholar.cc/episode/kxaxhkpkec

  8. Sep 8

    This Week in Pulmonary — Sep 8, 2026

    Editor's Pick: European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension (European Respiratory Journal, 2026) Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning thoracic oncology, guideline updates in pulmonary hypertension and tobacco treatment, two negative randomised trials that should change what we offer patients, and… This week's papers: 1. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (… — The Lancet 2026 2. Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — New England Journal of Medicine 2026 3. Pulmonary Nodules. — New England Journal of Medicine 2026 4. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. — European Respiratory Journal 2026 5. Tobacco Treatment in the Inpatient Setting: An American College of Chest Physicians Clinical Practice Guideline. — Chest 2026 6. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled tria… — The Lancet 2026 7. Impairment of upper airway patency and CPAP effectiveness during obstructive sleep apnea treatment with expiratory pressure alleviation: a randomized study. — Chest 2026 8. Days Alive and Out of Hospital Around Lung Transplantation: Predictors and Clinical Implications. — Chest 2026 9. From donor to durable graft: modern paradigms in lung transplantation. — European Respiratory Journal 2026 10. Making Palliative Care Work in Chronic Respiratory Diseases: A Nurse-Led Model. — Chest 2026 Listen at https://audioscholar.cc/episode/azmcd54qxb

See All (25)

About

Pulmonary — a weekly podcast briefing of the most significant peer-reviewed pulmonary literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information